Immuneering
44 articles with Immuneering
-
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
3/28/2023
Immuneering Corporation, a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced that it has appointed Harold E. Brakewood as its Chief Business Officer.
-
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
3/6/2023
Immuneering Corporation today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business updates.
-
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
3/5/2023
Immuneering Corporation announced that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research special conference targeting RAS, held March 5-8, 2023, in Philadelphia.
-
Immuneering Announces Participation in March Investor Conferences - February 28, 2023
2/28/2023
Immuneering Corporation today announced that management will participate in two March investor conferences to share commentary around the company’s pipeline, platform, and business strategy.
-
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
2/27/2023
Immuneering Corporation announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Monday, March 6 after the close of trading.
-
Immuneering To Present at Guggenheim 2023 Oncology Conference
1/31/2023
Immuneering Corporation today announced that management will present at Guggenheim’s 2023 Oncology Conference to discuss the company’s pipeline, platform, and business strategy.
-
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
11/28/2022
Immuneering Corporation today announced that the first patient commenced treatment on November 21 in its Phase 1/2a (NCT05585320) clinical trial of lead asset, IMM-1-104. IMM-1-104 is designed to provide pan-RAS activity through deep cyclic inhibition of the MAPK pathway with once-daily dosing.
-
Immuneering Announces Participation in November 2022 Investor Conferences
11/3/2022
Immuneering Corporation announced that management will participate in three November investor conferences to share commentary around the Company’s pipeline, platform, and business strategy.
-
Immuneering Appoints Leah R. Neufeld as Chief People Officer
10/20/2022
Immuneering Corporation announced the appointment of Leah R. Neufeld to the newly created position of Chief People Officer, effective immediately.
-
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10/5/2022
Immuneering Corporation today announced it will present data on its second program IMM-6-415 in a poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 8-12, 2022 in Boston or virtually.
-
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
9/30/2022
Immuneering Corporation announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for IMM-1-104, paving the way for the company to initiate a Phase 1/2a clinical trial of this oral, once daily small molecule, in development for the treatment of advanced RAS mutant solid tumors.
-
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
-
It's been a busy week for research on rare diseases, with several clinical trials from AnaptysBio, Regenxbio, Sangamo and more posting results from ongoing activities.
-
Immuneering Announces Participation in September 2022 Investor Conferences
8/25/2022
Immuneering Corporation announced that management will participate in two September investor conferences to share commentary around the Company’s pipeline, platform, and business strategy.
-
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8/10/2022
Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, reported financial results for the second quarter ended June 30, 2022 and provided recent business highlights.
-
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022
7/6/2022
Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, announced that management will participate in William Blair Biotech Focus Conference 2022.
-
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/10/2022
Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.
-
Immuneering Announces Participation in Citi’s Biopharma VIRTUAL Co-Panel Day
5/5/2022
Immuneering Corporation today announced that management will participate in Citi’s Biopharma VIRTUAL Co-Panel Day to discuss software, artificial intelligence and bioinformatics in drug development.
-
Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference
4/1/2022
Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, announced that management will participate in Piper Sandler’s AI/ML Investor Conference to discuss software, artificial intelligence and bioinformatics in drug development.
-
Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
3/24/2022
Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, announced that management will present at the 21st Annual Needham Virtual Healthcare Conference to share commentary around the Company’s pipeline, platform, and business strategy.